Patents by Inventor Hans Dietrich Menssen

Hans Dietrich Menssen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MDM2 INHIBITORS FOR USE IN THE TREATMENT OR PREVENTION OF HEMATOLOGIC NEOPLASM RELAPSE AFTER HEMATOPOIETIC CELL TRANSPLANTATION
    Publication number: 20230338374
    Abstract: The invention relates to a mouse double minute 2 (MDM2) inhibitor for use in the treatment and/or prevention of a hematologic neoplasm relapse after hematopoietic cell transplantation (HCT) in a patient. In embodiments, the hematologic neoplasm is a leukaemia, preferably acute myeloid leukaemia (AML). Preferably, the patient received an allogeneic T cell transplantation, either together with the HCT and/or after HCT, such as at the time point of MDM2 administration.
    Type: Application
    Filed: September 21, 2021
    Publication date: October 26, 2023
    Inventors: Robert Zeiser, Justus Duyster, Hans Dietrich Menssen
  • Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart
    Patent number: 8796426
    Abstract: The present invention relates to a combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart and uses thereof.
    Type: Grant
    Filed: November 13, 2008
    Date of Patent: August 5, 2014
    Assignee: Philogen S.p.A.
    Inventors: Dario Neri, Hans Dietrich Menssen, Andreas Menrad, Christoph Schliemann
  • Use of radioactively labelled molecule specifically binding to ED-B fibronection in a method of treatment of Hodgkin lymphoma
    Publication number: 20110123444
    Abstract: The invention relates to the use of a radioactively labelled molecule specifically binding to ED-B fibronectin in a method of treatment for patients with Hodgkin lymphoma, in particular primary refractory Hodgkin lymphoma or recurrent Hodgkin lymphoma after chemotherapy, and for Hodgkin lymphoma patients scheduled for primary combined-modality therapy.
    Type: Application
    Filed: May 2, 2009
    Publication date: May 26, 2011
    Applicant: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Hans Dietrich Menssen, Jörg Pinkert
  • Combination of an anti-ED—B fibronectin domain antibody—IL-2 fusion protein and gemcitabine
    Patent number: 7851599
    Abstract: The invention refers to the use of L19IL2 for treatment of pancreatic cancer. In another embodiment, the invention relates to a combination (i) of a fusion protein, comprising an Interleukin 2 part and an antibody part, specifically recognizing the extra domain B of fibronectin (ED-B-fibronectin), and (ii) gemcitabine.
    Type: Grant
    Filed: April 4, 2007
    Date of Patent: December 14, 2010
    Assignee: Philogen S.p.A.
    Inventors: Andreas Menrad, Hans Dietrich Menssen, Karola Wagner
  • COMBINATION OF AN ANTI-EDB FIBRONECTIN ANTIBODY-IL-2 FUSION PROTEIN, AND A MOLECULE BINDING TO B CELLS, B CELL PROGENITORS AND /OR THEIR CANCEROUS COUNTERPART
    Publication number: 20100310454
    Abstract: The present invention relates to a combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart and uses thereof.
    Type: Application
    Filed: November 8, 2008
    Publication date: December 9, 2010
    Inventors: Dario Neri, Hans Dietrich Menssen, Andreas Menrad, Christoph Schliemann
  • COMBINATION OF AN ANTI-EDB FIBRONECTIN ANTIBODY-IL-2 FUSION PROTEIN, AND A MOLECULE BINDING TO B CELLS, B CELL PROGENITORS AND/OR THEIR CANCEROUS COUNTERPART
    Publication number: 20090202473
    Abstract: The present invention relates to a combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart and uses thereof.
    Type: Application
    Filed: November 13, 2008
    Publication date: August 13, 2009
    Inventors: Dario NERI, Hans Dietrich Menssen, Andreas Menrad, Christoph Schliemann
  • USE OF A FUSION PROTEIN TARGETING THE ED-B FIBRONECTIN DOMAIN FOR TREATMENT OF ATHEROSCLEROSIS
    Publication number: 20090117073
    Abstract: The present invention relates to the use of a fusion protein comprising an antibody part which specifically recognises ED-B fibronectin, an effector part and optionally one or more fusion protein linker(s) and/or antibody linker(s), for the manufacturing of medicaments for the treatment and prevention of atherosclerosis
    Type: Application
    Filed: October 30, 2007
    Publication date: May 7, 2009
    Inventors: Andreas Menrad, Hans Dietrich Menssen, Kristof Graf
  • Combination of an anti-ED - B fibronectin domain antibody - IL-2 fusion protein and gemcitabine
    Publication number: 20090110660
    Abstract: The invention refers to the use of L19IL2 for treatment of pancreatic cancer. In another embodiment, the invention relates to a combination (i) of a fusion protein, comprising an Interleukin 2 part and an antibody part, specifically recognising the extra domain B of fibronectin (ED-B-fibronectin), and (ii) gemcitabine.
    Type: Application
    Filed: April 4, 2007
    Publication date: April 30, 2009
    Inventors: ANDREAS MENRAD, HANS DIETRICH MENSSEN, KAROLA WAGNER
  • Method of carrying out blood tests
    Patent number: 6521460
    Abstract: The present invention relates to a method of carrying out blood tests. The invention is based on the finding that clinico-chemical blood parameters can be determined using not only blood serum but also blood plasma. Therefore, freshly taken blood samples, which are mixed with at least one thrombin inhibitor, can be used for determining both clinico-chemical parameters and hematological parameters. The clinico-chemical parameters can thus be determined using blood plasma, a separation of coagulable components being not required any more.
    Type: Grant
    Filed: February 8, 1999
    Date of Patent: February 18, 2003
    Assignee: Rhein Biotech Gesellschaft fur Neue Biotechnologische Prozesse und Produkte mbH
    Inventors: Alexander W. M. Strasser, Karl Melber, Hans Dietrich Menssen, Eckard Thiel